CAR-T 세포 치료 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of CAR-T cell therapy Market

The global CAR-T cell therapy market is experiencing strong expansion due to rising cancer prevalence, rapid advancements in immunotherapy, and increasing investment in personalized medicine. CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of cancer treatment that modifies a patient's T-cells to recognize and destroy cancer cells, offering targeted and durable responses in hematologic malignancies.

Market Size and Forecast

According to the industry data:

• 2025 Market Size: USD 8.95 billion
• 2026 Market Size: USD 10.92 billion
• 2034 Market Forecast: USD 19.25 billion
• CAGR (2026-2034): 7.34%

The market is expected to nearly double between 2025 and 2034, reflecting strong long-term adoption of CAR-T therapies in oncology treatment pathways.

Regional Market Overview

North America (Market Leader)

• 2025 Value: USD 6.3 billion
• 2026 Value: USD 7.73 billion
• Share in 2025: 70.41% of global market

North America dominates the CAR-T cell therapy market due to advanced healthcare infrastructure, strong reimbursement systems, high cancer incidence, and early adoption of innovative therapies. The United States remains the key revenue generator in this region.

Europe

• 2025 Value: USD 1.67 billion
• 2026 Value: USD 2.01 billion
• Share in 2025: 18.67%

Europe shows steady growth supported by government funding, clinical research programs, and increasing regulatory approvals for CAR-T products.

Asia Pacific (Fastest Growing Region)

• 2025 Value: USD 0.80 billion
• 2026 Value: USD 0.99 billion
• Share in 2025: 8.94%

Asia Pacific is expected to record the highest growth rate due to rising cancer cases, expanding clinical trials, and increasing healthcare investments in countries like China, Japan, and India.

Rest of the World

• 2025 Value: USD 0.17 billion
• 2026 Value: USD 0.20 billion
• Share in 2025: 1.97%

Growth in this region is supported by improving healthcare infrastructure and gradual expansion of oncology treatment access.

Market Drivers

The CAR-T cell therapy market is driven by several key factors:

• Rising global incidence of hematologic cancers such as leukemia, lymphoma, and multiple myeloma
• Increasing approvals of CAR-T therapies by regulatory bodies like the FDA and EMA
• Expansion of clinical trials, with over 440 pipeline candidates in 2023
• Advancements in gene editing technologies such as CRISPR
• Growth in patient assistance programs and healthcare awareness initiatives
• Increasing collaborations between biotech and pharmaceutical companies

Market Trends

Major trends shaping the industry include:

• Shift toward allogeneic (off-the-shelf) CAR-T therapies, improving scalability and reducing treatment time
• Expansion of R&D partnerships (e.g., BioNTech-Autolus collaborations)
• Rapid growth in clinical pipeline and experimental CAR-T therapies
• Increasing focus on treating multiple indications beyond blood cancers

Market Restraints

Despite strong growth, the market faces challenges:

• High treatment cost ranging from USD 373,000 to over USD 1 million per patient
• Limited patient eligibility due to strict treatment conditions
• Complex manufacturing and personalized production processes
• Lack of reimbursement support in emerging economies

These factors restrict widespread adoption, particularly in low- and middle-income countries.

Segmentation Overview

• By Drug Type: Axicabtagene ciloleucel (Yescarta) leads the market
• By Indication: Non-Hodgkin lymphoma dominates with over 65% share
• By End User: Hospitals hold the largest share due to complex treatment requirements

Competitive Landscape

Key players include:

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson (Janssen)
• Caribou Biosciences, Inc.
• JW Therapeutics
• CARsgen Therapeutics

Gilead Sciences leads the market primarily through strong sales of Yescarta, while Bristol-Myers Squibb continues expanding its CAR-T pipeline globally.

Conclusion

The global CAR-T cell therapy market is on a strong growth trajectory, projected to increase from USD 8.95 billion in 2025 to USD 10.92 billion in 2026, and further reach USD 19.25 billion by 2034. Driven by rising cancer burden, technological advancements, and expanding clinical applications, CAR-T therapy is expected to become a cornerstone of next-generation oncology treatment despite challenges related to cost and accessibility.

Segmentation By Drug Type

• Axicabtagene Ciloleucel (Yescarta)
• Brexucabtagene Autoleucel (Tecartus)
• Ciltacabtagene Autoleucel (Carvykti)
• Idecabtagene Vicleucel (Abecma)
• Lisocabtagene Maraleucel (Breyanzi)
• Tisagenlecleucel (Kymriah)
• Others

By Indication

• Acute Lymphoblastic Leukemia
• Non-Hodgkin Lymphoma
• Multiple Myeloma

By End-user

• Hospitals
• Oncology Treatment Centers

By Region

• North America (By Drug Type, By Indication, By End-user, By Country)
  • U.S.
  • Canada
• Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Drug Type, By Indication, By End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Chronic Diseases, by Key Countries/Regions, 2025/2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Technological Advancements
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Type
  • 5.1.1. Axicabtagene Ciloleucel (Yescarta)
  • 5.1.2. Brexucabtagene Autoleucel (Tecartus)
  • 5.1.3. Ciltacabtagene Autoleucel (Carvykti)
  • 5.1.4. Idecabtagene Vicleucel (Abecma)
  • 5.1.5. Lisocabtagene Maraleucel (Breyanzi)
  • 5.1.6. Tisagenlecleucel (Kymriah)
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Acute lymphoblastic leukemia
  • 5.2.2. Non-Hodgkin lymphoma
  • 5.2.3. Multiple Myeloma
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Oncology Treatment Centers
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Type
  • 6.1.1. Axicabtagene Ciloleucel (Yescarta)
  • 6.1.2. Brexucabtagene Autoleucel (Tecartus)
  • 6.1.3. Ciltacabtagene Autoleucel (Carvykti)
  • 6.1.4. Idecabtagene Vicleucel (Abecma)
  • 6.1.5. Lisocabtagene Maraleucel (Breyanzi)
  • 6.1.6. Tisagenlecleucel (Kymriah)
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Acute lymphoblastic leukemia
  • 6.2.2. Non-Hodgkin lymphoma
  • 6.2.3. Multiple Myeloma
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Oncology Treatment Centers
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Type
  • 7.1.1. Axicabtagene Ciloleucel (Yescarta)
  • 7.1.2. Brexucabtagene Autoleucel (Tecartus)
  • 7.1.3. Ciltacabtagene Autoleucel (Carvykti)
  • 7.1.4. Idecabtagene Vicleucel (Abecma)
  • 7.1.5. Lisocabtagene Maraleucel (Breyanzi)
  • 7.1.6. Tisagenlecleucel (Kymriah)
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Acute lymphoblastic leukemia
  • 7.2.2. Non-Hodgkin lymphoma
  • 7.2.3. Multiple Myeloma
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Oncology Treatment Centers
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Type
  • 8.1.1. Axicabtagene Ciloleucel (Yescarta)
  • 8.1.2. Brexucabtagene Autoleucel (Tecartus)
  • 8.1.3. Ciltacabtagene Autoleucel (Carvykti)
  • 8.1.4. Idecabtagene Vicleucel (Abecma)
  • 8.1.5. Lisocabtagene Maraleucel (Breyanzi)
  • 8.1.6. Tisagenlecleucel (Kymriah)
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Acute lymphoblastic leukemia
  • 8.2.2. Non-Hodgkin lymphoma
  • 8.2.3. Multiple Myeloma
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Oncology Treatment Centers
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Type
  • 9.1.1. Axicabtagene Ciloleucel (Yescarta)
  • 9.1.2. Brexucabtagene Autoleucel (Tecartus)
  • 9.1.3. Ciltacabtagene Autoleucel (Carvykti)
  • 9.1.4. Idecabtagene Vicleucel (Abecma)
  • 9.1.5. Lisocabtagene Maraleucel (Breyanzi)
  • 9.1.6. Tisagenlecleucel (Kymriah)
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Acute lymphoblastic leukemia
  • 9.2.2. Non-Hodgkin lymphoma
  • 9.2.3. Multiple Myeloma
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Oncology Treatment Centers

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Gilead Sciences, Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Novartis AG
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Bristol-Myers Squibb Company
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Caribou Biosciences, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. CARsgenTherapeutics Co., Ltd
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. JW Therapeutics (Shanghai) Co., Ltd.
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & Services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Cartesian Therapeutics, Inc.
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & Services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Aurora Biopharma
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & Services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)